about
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced CancerNew modalities of cancer treatment for NSCLC: focus on immunotherapyNanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein traffickingStructural basis of human DNA polymerase η-mediated chemoresistance to cisplatin.Transition Metal Intercalators as Anticancer Agents-Recent AdvancesPreventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer TherapyMR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound.Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus).p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin.Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancerDibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes.Metabolic interrogation as a tool to optimize chemotherapeutic regimens.Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells.Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells.Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: in vitro and in vivo study.Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin.Protective effect of bilberry (Vaccinium myrtillus L.) on cisplatin induced ovarian damage in ratPlatinum nanoparticles induce damage to DNA and inhibit DNA replicationTumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy.Peptide targeting of platinum anti-cancer drugsSodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC)Cytotoxic Effects of Newly Synthesized Palladium(II) Complexes of Diethyldithiocarbamate on Gastrointestinal Cancer Cell Lines.Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1.Cellular responses to Cisplatin-induced DNA damage.Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report.Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.Combining aspects of the platinum anticancer drugs picoplatin and BBR3464 to synthesize a new family of sterically hindered dinuclear complexes; their synthesis, binding kinetics and cytotoxicity.Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay.hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis.Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancerPretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination.Erk in kidney diseases.Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells.CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma.Synergistic cytotoxicity of cisplatin and Taxol in overcoming Taxol resistance through the inhibition of LDHA in oral squamous cell carcinoma.Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancerMCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells.
P2860
Q26795509-567B8506-29D0-4414-9434-E0C89549003AQ26829161-F953F97C-87ED-4744-B101-D1CB58B62443Q27011482-7B16F650-0D1E-4B88-8231-F667F6D35AACQ27678705-433819D1-5CBC-4C23-B1EB-777E6DA4F741Q28077365-129AACF3-F04F-4BC9-8378-62F348B92E00Q28084568-E6166786-11C7-4D82-995C-162DD060FBFEQ30252977-6C417FCB-5AA5-47A1-9DE8-6C9BCF137C01Q30436557-70E2F178-83FE-40E3-8659-747B8F7EF3C5Q31008408-F7305AC3-BBB3-4E23-A18F-7DB9D2A5672DQ33463860-7ADF2464-E1E3-4C4C-82F3-C8AC79535D09Q33518618-A918FE4B-7829-401B-9008-E02F8EFA87F5Q33566853-1B7A7C74-A99D-4DC3-A045-C8FF5E3C49F4Q33622549-0D7F949D-1C72-4C7A-939C-20DD6F5A8AD7Q33686970-36DD449B-1808-4FB8-993E-4F9175F8B20EQ33725416-190528B8-989D-4C10-AEAD-B70829FB6057Q33781389-9CAF5990-4688-4313-B0C2-1FC05CF67CD6Q33849451-01133215-9A43-4DCB-AC16-70F9EDBA0AE4Q33898518-CF2C8D37-902C-4FDE-BABB-52F28D1677BBQ33903723-08A443F7-404C-456C-ABA1-BFBD66633278Q33937941-B28074DF-53E3-43D5-A65B-17F85C1716DEQ33940195-DDC5B339-847F-4920-82D2-122A73C2E8A0Q34039344-0737C92A-C9EE-428C-9D11-CC280EBFD5EFQ34059205-D532F355-E6D2-4CEB-9225-E0862CE0372FQ34089685-46A67313-3593-4889-A54F-1C7685AB283DQ34142424-BC596E79-1B91-4B42-8E83-FF293E56D08DQ34285363-108C03CB-69C6-492F-A2D3-2583D77E21A0Q34377003-3D888CB3-477B-43FF-AF6D-B510AEB5EB11Q34629768-66416DFF-9282-4438-BC5B-F8BCFA644492Q34695775-C23B7842-E5BF-48D8-BC3F-6821044E2247Q34704011-4A806F8A-F4FA-425A-8BEA-93331CBCCCC3Q34732544-20478D4E-5C99-4148-8081-1B3D10DD8FA6Q35101922-8F2B0B09-9202-49A9-ADB3-F0A7724C8FBFQ35103648-52C0930B-077F-44BA-92D8-DEE3428F4C37Q35122888-716206B5-C658-4DA0-9195-52D85EA43514Q35167498-4026BC65-ECA9-48D0-9073-35E18CCAA7DDQ35257063-7CE46520-3DC5-4E4F-AAA8-B55D5E7481AFQ35572426-212F27B3-5AEE-41F1-A8E4-A9EC038FB25FQ35632142-AC940327-DE15-4696-BE78-A8C48E1657AEQ35727617-48486C96-9B76-4B4F-990E-A2750FA88523Q35755480-08EA81C9-8255-43CC-AAC4-13EC1287A54F
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Biochemical mechanisms of cisplatin cytotoxicity.
@ast
Biochemical mechanisms of cisplatin cytotoxicity.
@en
type
label
Biochemical mechanisms of cisplatin cytotoxicity.
@ast
Biochemical mechanisms of cisplatin cytotoxicity.
@en
prefLabel
Biochemical mechanisms of cisplatin cytotoxicity.
@ast
Biochemical mechanisms of cisplatin cytotoxicity.
@en
P2093
P1476
Biochemical mechanisms of cisplatin cytotoxicity.
@en
P2093
Carlos Alonso
Celia Quevedo
Jose M Pérez
Josefina Castilla
Miguel A Fuertes
Victoria Cepeda
P356
10.2174/187152007779314044
P577
2007-01-01T00:00:00Z